U.S. Markets close in 5 hrs 16 mins

Athersys, Inc. (ATHX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.45-0.01 (-0.68%)
As of 10:41AM EDT. Market open.
People also watch
CYTXCURPSTIOPXACYCC

Athersys, Inc.

3201 Carnegie Avenue
Cleveland, OH 44115
United States
216-431-9900
http://www.athersys.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees60

Key Executives

NameTitlePayExercisedAge
Dr. Gil Van Bokkelen Ph.D.Co-Founder, Chairman and Chief Exec. Officer659.24kN/A56
Mr. William B. J. Lehmann Jr., J.D., MBAPres, Chief Operating Officer and Sec.506.97kN/A51
Dr. John J. Harrington Ph.D.Co-Founder, Chief Scientific Officer, Exec. VP and Director502.1kN/A50
Ms. Laura K. Campbell CPASr. VP of Fin.335.2kN/A53
Dr. Manal Morsy M.D., PH.D.VP of Global Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Corporate Governance

Athersys, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 2; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.